Delcath Systems failed to impress the FDA with its cancer drug delivery system Melblez, as the U.S. authority asked the company in a complete response letter for further trials before the chemotherapy device can move forward.
Civitas Therapeutics picked up $38 million in second-round financing to finish a Phase IIb trial and begin Phase III for its ARCUS respiratory delivery platform to treat Parkinson's disease.
Researchers at Penn State University have developed microcapsules to deliver brain cancer drugs in a targeted and controlled way--and the consistently uniform particles would be easy to manufacture, they say.
Using a similar method they once used to treat breast cancer, researchers at UCLA are employing nanodiamonds to deliver cancer drugs to the brain, providing treatment for the particularly aggressive glioblastoma.
German respiratory disease specialist Activaero has teamed up with Italy's Chiesi Farmaceutici to research the potential for a novel drug-device combination to treat cystic fibrosis using their respective technologies.
Oramed, the Jerusalem-based developer of two oral diabetes products in clinical trials, landed approval for a Chinese patent of its core technology from the country's State Intellectual Property Office.
Swiss devicemaker CeQur secured $27 million in a second round of financing, which the company says will help bring its CE marked PaQ insulin pump into higher-volume manufacturing. The company also aims to begin navigating the U.S. regulatory process early next year.
Capsugel, a specialist in the manufacture and sale of drug capsules, acquired Oregon's Bend Research for an undisclosed amount, getting hold of the company's formulation technology that increases compounds' stability. The terms of the agreement remain under wraps, and Capsugel expects to close the deal in 30 days.
Novan Therapeutics landed $78 million from the U.S. Biomedical Advanced Research and Development Authority to further develop the North Carolina-based company's technology that delivers nitric oxide gas to thermal wounds.
Researchers at McGill University in Montreal, Canada, have developed three-dimensional, nanosized cubes made of DNA that can be used to deliver drugs. It marks the first time molecules have been carried within DNA without being attached to the genetic material itself.
Researchers have developed self-powered nanoparticles to carry drugs into tiny cracks in bones, a process that could help treat osteoporosis in its early stages. And the fuel for the nanovehicles' bone-delving ability comes from the bone itself.
Google's venture arm is one of three firms contributing to an investment of more than $10 million in Rani Therapeutics, a drug-delivery company focusing on novel oral treatments.
Swedish pharmaceutical Meda bought Massachusetts-based Acton Pharmaceuticals, the maker of a new asthma drug-device combo, for $135 million plus milestone payments.
Jerusalem-based Oramed submitted a pre-IND application to the FDA for another of its oral insulin capsules, this one containing exenatide, a hormone that stimulates the secretion of insulin by the pancreas.
Researchers have come up with a way to see what cancer drugs will do in specific patients by mimicking the way human capillaries carry them in the body, making it possible to fine-tune the drugs' targeting mechanisms before conducting pricey, invasive lab tests.
Researchers in Singapore have created silicon "nanocages" to carry protein-based drugs past the body's natural defenses.
Swedish drug delivery company Lipidor welcomed positive results from a Phase I/IIa study of its water-free, lipid psoriasis treatment. The company, half-owned by Karolinska Development, touts the spray innovation as the first of its kind for topical drug delivery.
Ceptaris Therapeutics won FDA approval for its topical treatment for mycosis fungoides, the most common form of cutaneous T-cell lymphoma. The gel delivers the chemotherapeutic agent mechlorethamine, previously only approved for intravenous treatment.
Gold nanoparticles have been known for years to have cell-penetrating properties that make them excellent candidates for uses in drug delivery. But what makes them so special in the nanotech arena? A team of professors at MIT and in the Ecole Polytechnique de Lausanne in Swtizerland may have found the answer.
Novo Nordisk landed FDA clearance of its insulin injection pen that allows for fine dose adjustments--important for children--and a memory function to record the time since the last injection.